BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 3896476)

  • 21. Diethyldithiocarbamate inhibition of murine bone marrow toxicity caused by cis-diamminedichloroplatinum(II) or diammine-(1,1-cyclobutanedicarboxylato)platinum(II).
    Gringeri A; Keng PC; Borch RF
    Cancer Res; 1988 Oct; 48(20):5708-12. PubMed ID: 2844391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diethyldithiocarbamate modulation of murine bone marrow toxicity induced by cis-diammine(cyclobutanedicarboxylato)platinum (II).
    Schmalbach TK; Borch RF
    Cancer Res; 1989 Dec; 49(23):6629-33. PubMed ID: 2555048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ascorbato(1,2-diaminocyclohexane):platinum(II) complexes, a new series of water-soluble antitumor drugs.
    Hacker MP; Khokhar AR; Brown DB; McCormack JJ; Krakoff IH
    Cancer Res; 1985 Oct; 45(10):4748-53. PubMed ID: 4040806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative studies of DNA cross-linking and cytotoxicity in Burkitt's lymphoma cell lines treated with cis-diamminedichloroplatinum(II) and L-phenylalanine mustard.
    Ducore JM; Erickson LC; Zwelling LA; Laurent G; Kohn KW
    Cancer Res; 1982 Mar; 42(3):897-902. PubMed ID: 7199380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, cytotoxicity and antitumor activity of platinum(II) complexes of cyclopentanecarboxylic acid hydrazide.
    Kushev D; Gorneva G; Taxirov S; Spassovska N; Grancharov K
    Biol Chem; 1999 Nov; 380(11):1287-94. PubMed ID: 10614821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.
    Dedon PC; Borch RF
    Biochem Pharmacol; 1987 Jun; 36(12):1955-64. PubMed ID: 2954556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
    Ali-Osman F; Berger MS; Rajagopal S; Spence A; Livingston RB
    Cancer Res; 1993 Dec; 53(23):5663-8. PubMed ID: 8242621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.
    Fram RJ; Woda BA; Wilson JM; Robichaud N
    Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
    J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections.
    Terheggen PM; Floot BG; Scherer E; Begg AC; Fichtinger-Schepman AM; den Engelse L
    Cancer Res; 1987 Dec; 47(24 Pt 1):6719-25. PubMed ID: 3315190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity.
    Plooy AC; van Dijk M; Lohman PH
    Cancer Res; 1984 May; 44(5):2043-51. PubMed ID: 6538808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.
    Swinnen LJ; Barnes DM; Fisher SG; Albain KS; Fisher RI; Erickson LC
    Cancer Res; 1989 Mar; 49(6):1383-9. PubMed ID: 2924295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Water-soluble N-substituted iminodiacetato(1,2-diaminocyclohexane)-platinum(II) complexes as potential antitumor agents.
    Hacker MP; Khokhar AR; Krakoff IH; Brown DB; McCormack JJ
    Cancer Res; 1986 Dec; 46(12 Pt 1):6250-4. PubMed ID: 3779645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The formation of DNA interstrand cross-links by a novel bis-[Pt2Cl4(diminazene aceturate)2]Cl4.4H2O complex inhibits the B to Z transition.
    González VM; Fuertes MA; Jiménez-Ruíz A; Alonso C; Pérez JM
    Mol Pharmacol; 1999 Apr; 55(4):770-7. PubMed ID: 10101036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor activity and cross-resistance studies with Pt-ascorbato complexes.
    Hrubisko M; Balázová E; Kiss F; Kovácová J; Ujházy V
    Neoplasma; 1989; 36(6):651-7. PubMed ID: 2615869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of two second generation platinum antitumor drugs with mouse thymocytes.
    Simpkins H; Pearlman LF
    Cancer Res; 1986 Mar; 46(3):1433-9. PubMed ID: 3510724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity.
    Zwelling LA; Anderson T; Kohn KW
    Cancer Res; 1979 Feb; 39(2 Pt 1):365-9. PubMed ID: 570092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
    Holzer AK; Manorek GH; Howell SB
    Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
    Roberts JJ; Friedlos F
    Cancer Res; 1987 Jan; 47(1):31-6. PubMed ID: 3791217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.